Clinical Trial Update: Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and antitumor activity of Lete-Cel (GSK3377794) in HLA-A2+ patients with NY-ESO-1 positive, previously untreated advanced synovi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myxoid Liposarcoma
• Round Cell Liposarcoma
• Synovial Sarcoma

Drugs mentioned

• Lete-Cel (GSK3377794)

Snippet

Sponsor: USWM, LLC (dba US WorldMeds) | Conditions: Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-10-16